• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.慢性丙型肝炎患者接受阿片类激动剂治疗的治疗:最佳实践综述。
Infect Dis Clin North Am. 2018 Jun;32(2):347-370. doi: 10.1016/j.idc.2018.02.001.
2
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.注射吸毒者抗病毒治疗成功后的丙型肝炎再感染:一项荟萃分析。
J Hepatol. 2020 Apr;72(4):643-657. doi: 10.1016/j.jhep.2019.11.012. Epub 2019 Nov 27.
3
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.
4
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.加拿大注射毒品的艾滋病毒-丙型肝炎病毒合并感染者在丙型肝炎病毒预防和护理方面存在的差距。
Int J Drug Policy. 2022 May;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub 2022 Feb 24.
5
Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.在低门槛的初级卫生保健阿片类激动剂治疗方案中,直接作用抗病毒治疗丙型肝炎的依从性支持的可行性和可接受性。
Drug Alcohol Rev. 2019 Feb;38(2):185-189. doi: 10.1111/dar.12903. Epub 2019 Feb 13.
6
Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.需要替代疗法的注射吸毒者中抗病毒药物的药物相互作用。
Ann Pharmacother. 2015 Jul;49(7):796-807. doi: 10.1177/1060028015581848. Epub 2015 Apr 22.
7
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.在丙型肝炎病毒直接作用抗病毒治疗期间和之后,使用直接作用抗病毒药物治疗的近期注射吸毒或接受阿片类激动剂治疗者的药物和酒精使用模式及注射设备共用情况:一项国际研究。
Clin Infect Dis. 2020 May 23;70(11):2369-2376. doi: 10.1093/cid/ciz633.
8
The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.直接作用抗病毒药物(DAA)时代阿片类激动剂维持治疗对吸毒人群丙型肝炎病毒治疗启动的影响:一项基于人群的研究。
Clin Infect Dis. 2022 Mar 1;74(4):575-583. doi: 10.1093/cid/ciab546.
9
Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.直接作用抗病毒疗法治疗接受阿片类激动剂治疗或海洛因辅助治疗的丙型肝炎感染。
Int J Drug Policy. 2018 Dec;62:74-77. doi: 10.1016/j.drugpo.2018.10.003. Epub 2018 Oct 24.
10
Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.简化算法和综合 HCV 护理模式是否能提高注射吸毒人群的治疗关联、保留率和治愈率?一项实用的质量改进随机对照试验方案。
BMC Infect Dis. 2024 Jan 19;24(1):105. doi: 10.1186/s12879-024-08982-1.

引用本文的文献

1
Outcomes of Low Barrier Hepatitis C Treatment in High Risk Populations From Primary Care.基层医疗中高危人群低门槛丙型肝炎治疗的结果
J Community Hosp Intern Med Perspect. 2024 Nov 2;14(6):10-17. doi: 10.55729/2000-9666.1404. eCollection 2024.
2
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study.肯塔基州医疗补助计划中同时患有阿片类物质使用障碍的丙型肝炎患者的治疗:一项横断面研究。
J Gen Intern Med. 2025 Jan 21. doi: 10.1007/s11606-025-09356-2.
3
Influence of polysubstance use on the health-related quality of life among people who inject drugs undergoing opioid agonist treatment following treatment for hepatitis c virus.多药使用对丙型肝炎病毒治疗后接受阿片类激动剂治疗的注射吸毒者健康相关生活质量的影响。
J Subst Use. 2024;29(5):836-842. doi: 10.1080/14659891.2023.2254391. Epub 2023 Sep 6.
4
Frame Shift: Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized With Infections.移码突变:关注感染住院吸毒者的减少伤害和共同决策。
Clin Infect Dis. 2024 Feb 17;78(2):e12-e26. doi: 10.1093/cid/ciad664.
5
Facing HCV as a Major Public Healthcare Threat in Italy: Epidemiology and Micro-Elimination Pathways among Underserved Populations.将丙型肝炎病毒视为意大利主要公共卫生威胁:弱势群体中的流行病学与微观消除途径
Healthcare (Basel). 2023 Jul 24;11(14):2109. doi: 10.3390/healthcare11142109.
6
Racial Disparity in HCV Demographics and Treatment Between Interferon Era (2002-2003) and Direct Acting Anti-viral Era (2019).2002 - 2003年干扰素时代与2019年直接抗病毒药物时代丙型肝炎病毒人口统计学和治疗方面的种族差异
Cureus. 2023 Mar 24;15(3):e36643. doi: 10.7759/cureus.36643. eCollection 2023 Mar.
7
Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico.新墨西哥州农村县注射吸毒青年丙型肝炎病毒感染的护理级联
Public Health Rep. 2023 Nov-Dec;138(6):936-943. doi: 10.1177/00333549221143086. Epub 2023 Jan 12.
8
Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel.监狱服刑人员丙型肝炎病毒感染的快速诊断、分期及治疗:专家意见小组
Front Public Health. 2022 Oct 4;10:926414. doi: 10.3389/fpubh.2022.926414. eCollection 2022.
9
Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.在一家私人诊所,丙型肝炎综合治疗与改善阿片类药物使用障碍门诊治疗的留存率及成功率相关。
Front Psychiatry. 2022 Sep 14;13:932306. doi: 10.3389/fpsyt.2022.932306. eCollection 2022.
10
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).真实世界中慢性丙型肝炎病毒感染患者接受 Glecaprevir/Pibrentasvir 治疗的安全性、有效性和患者报告结局:德国丙型肝炎注册中心(DHC-R)的最新数据。
Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541.

本文引用的文献

1
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新:美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
2
Direct-acting antiviral agents for HCV infection affecting people who inject drugs.直接作用抗病毒药物治疗影响注射吸毒人群的 HCV 感染。
Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):641-651. doi: 10.1038/nrgastro.2017.106. Epub 2017 Aug 23.
3
High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.在城市基层医疗诊所,采用直接作用抗病毒药物治疗的吸毒者,其 HCV 治愈率较高。
Int J Drug Policy. 2017 Sep;47:196-201. doi: 10.1016/j.drugpo.2017.07.021. Epub 2017 Aug 12.
4
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.索磷布韦/维帕他韦在接受阿片类药物替代疗法的慢性丙型肝炎病毒感染患者中的疗效和安全性:3期ASTRAL试验分析
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.
5
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.在接受阿片类药物替代治疗的慢性 HCV 基因 1 型感染患者中,使用 Ledipasvir/Sofosbuvir 联合或不联合利巴韦林的疗效和安全性:ION 三期试验分析。
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.
6
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.依巴司韦/格拉瑞韦治疗接受阿片类激动剂治疗的丙型肝炎病毒感染者:一项随机试验。
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
7
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.在低门槛药物治疗机构采用不含干扰素的全口服方案对慢性丙型肝炎进行直接观察治疗——针对接受阿片类药物替代治疗且依从性存疑患者的一种新治疗理念。
Am J Gastroenterol. 2016 Jun;111(6):903-5. doi: 10.1038/ajg.2016.119.
8
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.丁丙诺啡、美沙酮与丙型肝炎治疗药物之间的药物相互作用。
Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):721-31. doi: 10.1080/17425255.2016.1183644. Epub 2016 May 30.
9
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.与NS3/4A蛋白酶抑制剂西米普明的药物相互作用。
Clin Pharmacokinet. 2016 Feb;55(2):197-208. doi: 10.1007/s40262-015-0314-y.
10
Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.达卡他韦与美沙酮或丁丙诺啡-纳洛酮之间药物相互作用的评估。
Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10. doi: 10.1128/AAC.00478-15. Epub 2015 Jun 29.

慢性丙型肝炎患者接受阿片类激动剂治疗的治疗:最佳实践综述。

Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

机构信息

Division of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, 3300 Kossuth Avenue, Bronx, NY 10467, USA.

Division of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, 3300 Kossuth Avenue, Bronx, NY 10467, USA.

出版信息

Infect Dis Clin North Am. 2018 Jun;32(2):347-370. doi: 10.1016/j.idc.2018.02.001.

DOI:10.1016/j.idc.2018.02.001
PMID:29778260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6022838/
Abstract

Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug-drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.

摘要

注射毒品是丙型肝炎最常见的传播途径。阿片类药物激动剂治疗者的感染率很高。尽管注射毒品者负担最重,但接受治疗的人却很少。我们全面回顾了丙型肝炎药物的疗效、药物相互作用以及治疗障碍和模式的证据。研究表明,接受阿片类药物激动剂治疗的个体与未接受治疗的个体相比,药物疗效相当。我们提出,在这一人群中,必须采取治疗和治愈即预防的策略,以遏制丙型肝炎的流行。